Wells Fargo & Company Issues Positive Forecast for Henry Schein (NASDAQ:HSIC) Stock Price

Henry Schein (NASDAQ:HSIC) had its price target boosted by analysts at Wells Fargo & Company from $70.00 to $76.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 6.32% from the company’s current price.

Other research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Robert W. Baird reiterated a “neutral” rating and issued a $72.00 price target (down from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Baird R W cut Henry Schein from a “strong-buy” rating to a “hold” rating in a report on Monday, July 14th. UBS Group decreased their price target on Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Finally, Stifel Nicolaus restated a “hold” rating and set a $75.00 price target (down from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Five analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $77.33.

Henry Schein Stock Performance

Shares of NASDAQ HSIC traded down $0.13 during trading on Wednesday, reaching $71.49. 320,280 shares of the stock traded hands, compared to its average volume of 1,716,495. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The stock has a market capitalization of $8.67 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 2.06 and a beta of 0.81. Henry Schein has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a 50-day moving average of $66.17 and a 200-day moving average of $68.61.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The business had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Analysts forecast that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the 2nd quarter valued at $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein in the second quarter valued at about $27,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein during the second quarter valued at about $43,000. Steph & Co. bought a new position in shares of Henry Schein during the second quarter valued at about $44,000. Finally, CX Institutional boosted its holdings in shares of Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after purchasing an additional 337 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.